Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cohesinopathy Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SMC3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMC3 Recombinant Protein (ATPase Domain / Hinge Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View SMC3 Products |
| Gene Delivery | SMC3 Promise-ORF / Lentivirus Full-length human SMC3 ORF for stable cell line generation. |
View SMC3 Products |
| Benchmark Ab | Anti-SMC3 Recombinant Antibody Recombinant sequence-verified positive control for Western Blot and ChIP. |
View SMC3 Products |
| Validator | SMC3 siRNA Set Target-specific knockdown verification in cancer cell lines. |
View SMC3 Products |
| Related Target A | SMC1A Obligate heterodimerization partner of SMC3 in the core cohesin ring. |
View SMC1A Products |
| Related Target B | RAD21 Cleavable kleisin subunit essential for stabilizing the SMC1A-SMC3 complex. |
View RAD21 Products |
| Related Target C | STAG2 Cohesin subunit mutated in multiple cancers; target for synthetic lethality screening. |
View STAG2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large Protein Size & Complex Folding | Domain-specific truncations (ATPase head, coiled-coil, hinge) designed for high-yield expression in eukaryotic systems. |
| Heterodimer Reconstitution (SMC3/SMC1A) | Co-expressed or individually purified subunits verified by native gel electrophoresis and theoretical MW confirmation. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for target knockdown and specificity validation. |
Live SMC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the cohesin complex, particularly SMC3, represents an emerging frontier in oncology. As a core component of the ring-shaped cohesin complex, SMC3 is indispensable for sister chromatid cohesion, DNA damage repair, and 3D chromatin architecture maintenance. Recent clinical and genomic studies have highlighted the potential of exploiting cohesin vulnerabilities, particularly through synthetic lethality in STAG2-deficient tumors (common in bladder cancer, Ewing sarcoma, and acute myeloid leukemia).
The race for SMC3 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic agents to targeted small-molecule inhibitors of the SMC3 ATPase domain, PROTAC-mediated degraders, and RNA-targeting modalities. As first-generation cohesin pathway modulators enter pre-clinical validation, the next wave of R&D is targeting drug-resistant mutations and combination regimens with PARP inhibitors or DNA damage response (DDR) therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | AML, Colorectal Cancer, Bladder Cancer | ATPase activity assays & SPR binding (Need high-purity recombinant ATPase domain) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Biotechs | Solid Tumors, Hematological Malignancies | Ubiquitination & degradation assays (Need lentivirus for stable reporter line generation) |
| RNA Therapeutics (siRNA/ASO) | RNA Therapeutics Developers | Cornelia de Lange Syndrome (CdLS) models, Oncology | Target knockdown validation (Need sequence-verified control siRNA and qPCR primers) |